A bipartisan group of senators Feb. 2 released for stakeholder feedback a discussion draft of legislation to clarify in statute Congress’ intent for the 340B program to help safety net providers maintain, improve and expand patient access to health care services by requiring drug manufacturers that participate in Medicaid and Medicare Part B to provide discounts and rebates to covered entities that serve a disproportionate share of low-income and underserved patients. 

The draft Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act or the “SUSTAIN 340B Act” includes provisions intended to clarify that covered entities can use contract pharmacies in accordance with 2010 guidance from the Health Resources and Services Administration and associated requirements; and to clarify the definition of patient in the 340B statute. The draft bill also includes provisions intended to enhance program transparency and integrity and prevent duplicate discounts; and would require participating covered entities to pay a user fee of up to 0.01% of the savings they achieve under the 340B program, calculated as the difference between the wholesale acquisition cost and 340B price of the drugs purchased under the program. 

In an explanatory statement and Request for Information, Sens. John Thune, R-S.D., Debbie Stabenow, D-Mich., Shelly Moore Capito, R-W.Va., Tammy Baldwin, D-Wisc., Jerry Moran, R-Kan., and Benjamin Cardin, D-Md., specifically seek stakeholder feedback on how to achieve the correct balance of patient access, accountability and program integrity in contract pharmacy arrangements; how to appropriately structure the definition of patient; and how to ensure that “child sites” align with the program’s intent. 

Related News Articles

Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…